Related Experiment Video
Updated: Aug 21, 2026
Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting
Published on: December 9, 2022
Abnormal KCC2 expression and function in a mouse model of epilepsy and tuberous sclerosis complex
Dongjun Guo1, Lirong Han1, Nicholas R Rensing1
1Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
Objective:
Drug-resistant epilepsy is a common, severe manifestation of the genetic disorder tuberous sclerosis complex (TSC). Although significant mechanistic and therapeutic advances have been made in TSC, treatments for seizures remain largely ineffective. Decreased expression of the potassium-chloride cotransporter KCC2 is associated with depolarizing γ-aminobutyric acid (GABA) signaling and increased neuronal excitability in the immature brain and in certain pathological states. In this study, we investigated abnormalities in KCC2 expression and function in a mouse model of TSC-related epilepsy.
Methods:
Tsc1GFAPCKO mice were used to investigate KCC2 expression by Western blotting and immunohistochemistry. The effects of KCC2 pharmacological modulators on KCC2 expression and seizures in Tsc1GFAPCKO mice were tested by Western blotting and video-electroencephalography.
Results:
KCC2 expression was decreased in Tsc1GFAPCKO mice compared with controls, including prior to the onset of seizures. The decrease in KCC2 expression was reversed by the mTOR inhibitor rapamycin as well as select KCC2 modulators. These KCC2 modulators also decreased seizures in Tsc1GFAPCKO mice.
Significance:
Decreased KCC2 expression may lead to impaired GABAergic inhibition and increased neuronal excitability, contributing to epileptogenesis in TSC. Potentiation of KCC2 expression may represent a novel, effective therapeutic approach for epilepsy in TSC.
Insights
Drug-resistant epilepsy in tuberous sclerosis complex (TSC) involves decreased KCC2 expression, impairing GABAergic inhibition. Restoring KCC2 levels with modulators may offer a new therapeutic strategy for TSC-related seizures.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Drug-resistant epilepsy is a severe complication of tuberous sclerosis complex (TSC).
- Current treatments for TSC-related seizures are often ineffective.
- Reduced KCC2 transporter expression is linked to neuronal hyperexcitability and seizures.
Purpose of the Study:
- To investigate KCC2 expression and function in a mouse model of TSC-related epilepsy.
- To explore the therapeutic potential of KCC2 modulation for TSC epilepsy.
Main Methods:
- Utilized Tsc1GFAPCKO mice, a model for TSC-related epilepsy.
- Assessed KCC2 expression via Western blotting and immunohistochemistry.
- Evaluated the impact of KCC2 modulators and rapamycin on KCC2 levels and seizure activity using video-electroencephalography.
Main Results:
- KCC2 expression was significantly decreased in Tsc1GFAPCKO mice, even before seizure onset.
- Rapamycin and specific KCC2 modulators restored KCC2 expression.
- KCC2 modulators effectively reduced seizure frequency in the TSC mouse model.
Conclusions:
- Impaired KCC2 function contributes to epileptogenesis in TSC by reducing GABAergic inhibition.
- Enhancing KCC2 expression presents a promising novel therapeutic avenue for treating epilepsy in TSC patients.
